Skip to main content
SpringerLink
Log in

Malignant Glandular Lesions of the Cervix

  • Chapter
  • First Online:
Cellular Pathology of Glandular Lesions and Uncommon Neoplasms of the Cervix

  • 728 Accesses

Abstract

Cervical adenocarcinomas are increasing in incidence and now account for approximately 25 % of cervical carcinomas in most developed countries. Most are associated with high risk human papillomavirus (HPV) infection and are of the usual endocervical type. However, a minor proportion of unusual morphological subtypes of cervical adenocarcinoma are not HPV associated. This chapter covers the clinicopathological features of the various subtypes of cervical adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001;357:1490–3.

    PubMed  CAS  Google Scholar 

  2. Tavassoli FA, Devilee P, World Health Organisation Classification of Tumours. Pathology and genetics. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003.

    Google Scholar 

  3. Houghton O, Jamison J, Wilson R, Carson J, McCluggage WG. p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology. 2010;57:342–50.

    PubMed  Google Scholar 

  4. Park KJ, Kiyokawa T, Soslow RA, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35:633–46.

    PubMed  Google Scholar 

  5. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055–62.

    PubMed Central  PubMed  CAS  Google Scholar 

  6. Hee JA, Kim KR, Kim IS. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol. 2005;18:528–34.

    Google Scholar 

  7. Duggan MA, McGregor SE, Benoit JL, et al. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum Pathol. 1995;26:319–25.

    PubMed  CAS  Google Scholar 

  8. Tenti P, Romagnoli S, Silini E, et al. Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol. 1996;106:52–6.

    PubMed  CAS  Google Scholar 

  9. Skylderg BM, Murray E, Lambkin H, et al. Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod Pathol. 1999;12:675–82.

    Google Scholar 

  10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.

    PubMed  Google Scholar 

  11. Creasman WT. New gynecologic cancer staging. Gynecol Oncol. 1995;58:198–202.

    Google Scholar 

  12. Hirschowitz L, Ganesan R, Singh N, McCluggage WG. Dataset for the histological reporting of cervical neoplasia. London: Royal College of Pathologists; 2011.

    Google Scholar 

  13. McCluggage WG. Ten problematic issues identified by pathology review for multidisciplinary gynaecological oncology meetings. J Clin Pathol. 2012;65:293–301.

    PubMed  Google Scholar 

  14. McCluggage WG. Endocervical glandular lesions: controversial aspects and ancillary techniques. J Clin Pathol. 2003;56:164–73.

    PubMed Central  PubMed  CAS  Google Scholar 

  15. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185–207.

    PubMed  CAS  Google Scholar 

  16. Rollason TP, Cullimore J, Bradgate MG. A suggested columnar cell morphological equivalent of squamous carcinoma in situ with early stromal invasion. Int J Gynecol Pathol. 1989;8:230–6.

    PubMed  CAS  Google Scholar 

  17. Wheeler DT, Kurman RJ. The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol. 2005;24:125–30.

    PubMed  Google Scholar 

  18. Al-Kalbani M, McVeigh G, Nagar H, McCluggage WG. Do FIGO stage 1A and small (≤2 cm) 1B1 adenocarcinomas have a good prognosis and warrant less radical surgery? Int J Gynecol Cancer. 2012;26:291–8.

    Google Scholar 

  19. Negri G, Romano F, Vittadello F, et al. Laminin-5 gamma 2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cérvix uteri. Hum Pathol. 2006;37:704–10.

    PubMed  CAS  Google Scholar 

  20. Yavner DL, Dwyer IM, Hancock WW, Ehrmann RC. Basement membrane of cervical adenocarcinoma: an immunoperoxidase study of laminin and type IV collagen. Obstet Gynecol. 1990;76:1014–9.

    PubMed  CAS  Google Scholar 

  21. Jordan SM, Watanabe T, Osann K, Monk BJ, Lin F, Rutgers JK. Desmoplastic stromal response as defined by positive α-smooth muscle actin staining is predictive of invasion in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2012;31:369–76.

    PubMed  Google Scholar 

  22. Ostor AG. Early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2000;19:29–38.

    PubMed  CAS  Google Scholar 

  23. Ceballos KM, Shaw D, Daya D. Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. Am J Surg Pathol. 2006;30:370–4.

    PubMed  Google Scholar 

  24. Reynolds EA, Tierney K, Keeney G, et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol. 2010;116:1150–7.

    PubMed  Google Scholar 

  25. Balega J, Michael H, Hurteau J, et al. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix. Int J Gynecol Cancer. 2004;14:104–9.

    PubMed  CAS  Google Scholar 

  26. Smith HO, Qualls CR, Romero AA, et al. Is there a difference in survival for 1A1 and 1A2 adenocarcinoma of the uterine cervix? Gynecol Oncol. 2002;85:229–41.

    PubMed  Google Scholar 

  27. Yahata T, Nishino K, Kashima K, et al. Conservative treatment of stage 1A1 adenocarcinoma of the uterine cervix with a long-term follow-up. Int J Gynecol Cancer. 2010;20:1063–6.

    PubMed  Google Scholar 

  28. Smith JS, Green J, de Gonzalez Berrington A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159–67.

    PubMed  Google Scholar 

  29. Tambouret R, Bell DA, Young RH. Microcystic endocervical adenocarcinomas: a report of eight cases. Am J Surg Pathol. 2000;24:369–74.

    PubMed  CAS  Google Scholar 

  30. Young RH, Scully RE. Uterine carcinomas simulating microglandular hyperplasia: a report of six cases. Am J Surg Pathol. 1992;16:1092–7.

    PubMed  CAS  Google Scholar 

  31. Mansor S, McCluggage WG. Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto undescribed variant of primary cervical adenocarcinoma. Int J Gynecol Pathol. 2010;29:594–9.

    PubMed  Google Scholar 

  32. Shintaku M, Karlya M, Shime H, et al. Adenocarcinoma of the uterine cervix with choriocarcinomatous and hepatoid differentiation: report of a case. Int J Gynecol Pathol. 2000;19:174–8.

    PubMed  CAS  Google Scholar 

  33. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N. Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer. 2007;17:1150–4.

    PubMed  CAS  Google Scholar 

  34. McCluggage WG. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology. 2007;39:97–111.

    PubMed  CAS  Google Scholar 

  35. Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2010;34:915–26.

    PubMed  Google Scholar 

  36. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21:4–10.

    PubMed  Google Scholar 

  37. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11–5.

    PubMed  Google Scholar 

  38. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol. 1986;10:568–76.

    PubMed  CAS  Google Scholar 

  39. Savargaonkar PR, Hale RJ, Mutton A, Manning V, Buckley CH. Neuroendocrine differentiation in cervical carcinoma. J Clin Pathol. 1996;49:139–41.

    PubMed Central  PubMed  CAS  Google Scholar 

  40. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol. 2009;33:914–24.

    PubMed  Google Scholar 

  41. Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32:1835–53.

    PubMed  Google Scholar 

  42. Chang MC, Nevadunsky NS, Viswanathan AN, Crum CP, Feltmate CM. Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol. 2010;29:88–92.

    PubMed  Google Scholar 

  43. Eftekhar Z, Marsden D, Robertson G, et al. Prognostic factors and survival of adenocarcinoma of the cervix. Int J Gynecol Cancer. 2002;12:612.

    Google Scholar 

  44. Liu WX, Chen Y, Yang GM. Analysis of prognostic-related factors in patients with invasive cervical adenocarcinoma. Eur J Gynaecol Oncol. 2011;32:500–4.

    PubMed  CAS  Google Scholar 

  45. Hart WR. Symposium part II: special types of adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2002;21:327–46.

    PubMed  Google Scholar 

  46. McCluggage WG, Shah R, Connolly LE, McBride HA. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol. 2008;27:92–100.

    PubMed  CAS  Google Scholar 

  47. Lee KR, Trainer TD. Adenocarcinoma of the uterine cervix of intestinal type containing numerous Paneth cells. Arch Pathol Lab Med. 1990;114:731–3.

    PubMed  CAS  Google Scholar 

  48. Raspollini MR, Baroni G, Taddei A, et al. Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix. An investigation using cdx-2 and a limited immunohistochemical panel. Arch Pathol Lab Med. 2003;127:1586–90.

    PubMed  Google Scholar 

  49. Fox H, Wells M, Harris M, et al. Enteric tumors of the lower female genital tract: a report of three cases. Histopathology. 1988;12:167–76.

    PubMed  CAS  Google Scholar 

  50. Zhang PJ, Shah M, Spiegel GW, Brooks JJ. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003;11:306–10.

    PubMed  CAS  Google Scholar 

  51. Savargaonkar PR, Hale RJ, Pope R, Fox H, Buckley CH. Enteric differentiation in cervical adenocarcinomas and its prognostic significance. Histopathology. 1993;23:275–7.

    PubMed  CAS  Google Scholar 

  52. Suarez-Penaranda JM, Abdulkader I, Baron-Duarte FJ, Gonzalez Patino E, Novo-Dominguez A, Varela-Duran J. Signet-ring cell carcinoma presenting in the uterine cervix: report of a primary and 2 metastatic cases. Int J Gynecol Pathol. 2007;26:254–8.

    PubMed  Google Scholar 

  53. Balci S, Saglam A, Usubutun A. Primary signet-ring cell carcinoma of the cervix: case report and review of the literature. Int J Gynecol Pathol. 2010;29:181–4.

    PubMed  Google Scholar 

  54. Kupryjanczyk J, Kujawa M. Signet-ring cells in squamous cell carcinoma of the cervix and in non-neoplastic ectocervical epithelium. Int J Gynecol Pathol. 1992;2:152–6.

    Google Scholar 

  55. McKenna M, McCluggage WG. Signet ring cells of stromal derivation in the uterine cervix secondary to cauterisation: report of a previously undescribed phenomenon. J Clin Pathol. 2008;61:648–51.

    PubMed  CAS  Google Scholar 

  56. Gilks CB, Young RH, Aguirre P, et al. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol. 1989;13:717–29.

    PubMed  CAS  Google Scholar 

  57. Silverberg SG, Hurt WG. Minimal deviation adenocarcinoma (“adenoma malignum”) of the cervix: a reappraisal. Am J Obstet Gynecol. 1975;121:971–5.

    PubMed  CAS  Google Scholar 

  58. Menko FH. LKB1/SKT11. Peutz-Jeghers cancer syndrome and cancer. Fam Cancer. 2011;10:413–4.

    PubMed Central  PubMed  Google Scholar 

  59. Kuragaki C, Enomoto T, Ueno Y, et al. Mutations in the SKT11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest. 2003;83:35–46.

    PubMed  CAS  Google Scholar 

  60. Connolly DC, Katabuchi H, Cliby WA, Cho KR. Somatic mutations in the SKT11/LKB1 gene are uncommon in rare gynecologic tumor types associated with Peutz-Jegher’s syndrome. Am J Pathol. 2000;156:339–45.

    PubMed Central  PubMed  CAS  Google Scholar 

  61. Toki T, Zhai YL, Park JS, Fujii S. Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix. Int J Gynecol Pathol. 1999;18:215–9.

    PubMed  CAS  Google Scholar 

  62. Xu J, Hashi A, Kondo T, et al. Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol. 2005;24:296–302.

    PubMed  Google Scholar 

  63. Mikami Y, Kiyokawa T, Hata S, Fujiwara K, Moriya T, Sasano H, et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’. Mod Pathol. 2004;17:962–72.

    PubMed  Google Scholar 

  64. Nucci MR, Clement PB, Young RH. Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. Am J Surg Pathol. 1999;23:886–91.

    PubMed  CAS  Google Scholar 

  65. Mikami Y, McCluggage WG. Endocervical glandular lesions exhibiting gastric differentiation: an emerging spectrum of benign, premalignant and malignant lesions. Adv Anat Pathol. 2013;20:227–37.

    PubMed  CAS  Google Scholar 

  66. Tsuda H, Mikami Y, Kaku T, et al. Interobserver variation in the diagnosis of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. Pathol Int. 2003;53:440–9.

    PubMed  Google Scholar 

  67. Kondo T, Hashi A, Murata SI, et al. Gastric mucin is expressed in a subset of endocervical tunnel clusters: type A tunnel clusters of gastric phenotype. Histopathology. 2007;50:843–50.

    PubMed  CAS  Google Scholar 

  68. Ichimura T, Koizumi T, Tateiwa H, et al. Immunohistochemical expression of gastric mucin and p53 in minimal deviation adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2001;20:220–6.

    PubMed  CAS  Google Scholar 

  69. Toki T, Shiozawa T, Hosaka N, Ishii K, Nikaido T, Fujii S. Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors, CA125, and gastric mucin. Int J Gynecol Pathol. 1997;16:111–6.

    PubMed  CAS  Google Scholar 

  70. Utsugi K, Hirai Y, Takeshima N, et al. Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix. Gynecol Oncol. 1999;75:345–8.

    PubMed  CAS  Google Scholar 

  71. Michael H, Grawe L, Kraus FT. Minimal deviation endocervical adenocarcinoma: clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen, and differentiation from confusing benign lesions. Int J Gynecol Pathol. 1984;3:261–76.

    PubMed  CAS  Google Scholar 

  72. Mikami Y, Kiyokawa T, Moriya T, Sasano H. Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma (‘adenoma malignum’) and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology. 2005;46:130–6.

    PubMed  CAS  Google Scholar 

  73. Hayashi I, Tsuda H, Shimoda T. Reappraisal of orthodox histochemistry for the diagnosis of minimal deviation adenocarcinoma of the cervix. Am J Surg Pathol. 2000;24:559–62.

    PubMed  CAS  Google Scholar 

  74. Seidman JD. Mucinous lesions of the fallopian tube. Am J Surg Pathol. 1994;18:1205–12.

    PubMed  CAS  Google Scholar 

  75. Young RH, Scully RE. Mucinous tumors of the ovary associated with mucinous adenocarcinomas of the cervix. A clinicopathologic analysis of 16 cases. Int J Gynecol Pathol. 1988;7:99–111.

    PubMed  CAS  Google Scholar 

  76. Kojima A, Mikami Y, Sudo T, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31:664–72.

    PubMed  Google Scholar 

  77. Kusanagi Y, Kogima A, Mikami Y, et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol. 2010;177:2169–75.

    PubMed Central  PubMed  Google Scholar 

  78. McCluggage WG, Harley I, Houghton JP, Geyer FC, McKay A, Reis-Filho JS. Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in patient with Peutz-Jeghers syndrome. J Clin Pathol. 2010;63:935–41.

    PubMed  Google Scholar 

  79. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases. Int J Gynecol Pathol. 1993;12:1–7.

    PubMed  CAS  Google Scholar 

  80. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer. 1989;63:1773–9.

    PubMed  CAS  Google Scholar 

  81. Macdonald RD, Kirwan J, Hayat K, et al. Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis. Gynecol Oncol. 2006;100:192–4.

    PubMed  CAS  Google Scholar 

  82. Jones MW, Kounelis S, Papadaki H, et al. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/tumor suppressor alterations and human papillomavirus genotyping. Int J Gynecol Pathol. 2000;19:110–7.

    PubMed  CAS  Google Scholar 

  83. Heatley MK. Villoglandular adenocarcinoma of the uterine cervix-a systematic review of the literature. Histopathology. 2007;51:268–9.

    PubMed  CAS  Google Scholar 

  84. Alfsen GC, Thoresen SO, Kristensen GB, et al. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all groups. Cancer. 2000;89:1291–9.

    PubMed  CAS  Google Scholar 

  85. Zaino RJ. Glandular lesions of the uterine cervix. Mod Pathol. 2000;13:261–74.

    PubMed  CAS  Google Scholar 

  86. Hirschowitz L, Sen C, Murdoch J. Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia–a potential diagnostic pitfall. Diagn Pathol. 2007;2:40.

    PubMed Central  PubMed  Google Scholar 

  87. Rahilly MA, Williams AR, Al-Nafussi A. Minimal deviation endometrioid adenocarcinoma of cervix: a clinicopathological and immunohistochemical study of two cases. Histopathology. 1992;20:351–4.

    PubMed  CAS  Google Scholar 

  88. Young RH, Scully RE. Minimal-deviation endometrioid adenocarcinoma of the uterine cervix. A report of five cases of a distinctive neoplasm that may be misinterpreted as benign. Am J Surg Pathol. 1993;17:660–5.

    PubMed  CAS  Google Scholar 

  89. Kamoi S, Al Juboury ML, Akin MR, et al. Immunohistochemical staining in the distinction between endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002;21:217–23.

    PubMed  Google Scholar 

  90. Hanselaar A, van Loosbroek M, Schuurbiers O, Helmerhorst T, Bulten J, Bernhelm J. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer. 1997;79:2229–36.

    PubMed  CAS  Google Scholar 

  91. Herbst AL. Behaviour of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES). Gynecol Oncol. 2000;76:147–56.

    PubMed  CAS  Google Scholar 

  92. Kaminski PF, Maier RC. Clear cell adenocarcinoma of the cervix unrelated to diethylstilbestrol exposure. Obstet Gynecol. 1983;62:720–7.

    PubMed  CAS  Google Scholar 

  93. Matias-Guiu X, Lerma E, Prat J. Clear cell tumors of the female genital tract. Semin Diagn Pathol. 1997;14:233–9.

    PubMed  CAS  Google Scholar 

  94. Zhou C, Gilks CB, Hayes M, Clement PB. Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. Am J Surg Pathol. 1998;22:113–20.

    PubMed  CAS  Google Scholar 

  95. Nofech-Mozes S, Rasty G, Ismiil N, Covens A, Khalifa MA. Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer. 2006;16 Suppl 1:286–92.

    PubMed  Google Scholar 

  96. Clement PB, Young RH, Keh P, Ostor AG, Scully RE. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol. 1995;19:1158–71.

    PubMed  CAS  Google Scholar 

  97. Bague S, Rodriquez IM, Prat J. Malignant mesonephric tumors of the female genital tract. A clinicopathologic study of 9 cases. Am J Surg Pathol. 2004;28:601–7.

    PubMed  Google Scholar 

  98. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, Tavassoli FA. Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol. 2001;25:379–87.

    PubMed  CAS  Google Scholar 

  99. Kenny SL, McBride HA, Jamison J, McCluggage WG. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and Hepatocyte Nuclear Factor 1-β. Am J Surg Pathol. 2012;36:799–807.

    PubMed  Google Scholar 

  100. McCluggage WG, Oliva E, Herrington CS, McBride H, Young RH. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology. 2003;43:144–50.

    PubMed  CAS  Google Scholar 

  101. Ordi J, Ramagosa C, Tavassoli FA. CD10 expression in epithelial tissues and tumors of the gynecologic tract. Am J Surg Pathol. 2003;27:178–86.

    PubMed  Google Scholar 

  102. Seidman JD, Tavassoli FA. Mesonephric hyperplasia of the uterine cervix: a clinicopathologic study of 51 cases. Int J Gynecol Pathol. 1995;14:293–9.

    PubMed  CAS  Google Scholar 

  103. Gallup DG, Harper RH, Stock RJ. Poor prognosis in patients with adenosquamous cell carcinoma of the cervix. Obstet Gynecol. 1985;65:416–22.

    PubMed  CAS  Google Scholar 

  104. Lea JS, Coleman RL, Garner EO, et al. Adenosquamous histology predicts poor outcome in low-risk stage 1B1 cervical adenocarcinoma. Gynecol Oncol. 2003;91:558–62.

    PubMed  Google Scholar 

  105. Fujiwara H, Mitchell MF, Arseneau J, et al. Clear cell adenosquamous carcinoma of the cervix. An aggressive tumor associated with human papillomavirus-18. Cancer. 1995;76:1591–600.

    PubMed  CAS  Google Scholar 

  106. Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma? Cancer. 1995;76:1948–55.

    PubMed  CAS  Google Scholar 

  107. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer. 2003;97:2196–202.

    PubMed  Google Scholar 

  108. Samlal RA, Ten Kate FJ, Hart AA, Lammes FB. Do mucin-secreting squamous cell carcinomas of the uterine cervix metastasize more frequently to pelvic lymph nodes? A case-control study? Int J Gynecol Pathol. 1988;17:201–4.

    Google Scholar 

  109. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD. Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol. 2009;33:835–43.

    PubMed  Google Scholar 

  110. Littman P, Clement PB, Henriksen B, Wang CC, Robboy SJ, Taft PD, et al. Glassy cell carcinoma of the cervix. Cancer. 1976;37:2238–46.

    PubMed  CAS  Google Scholar 

  111. Kato N, Katayama Y, Kaimori M, Motoyama T. Glassy cell carcinoma of the uterine cervix: histochemical, immunohistochemical, and molecular genetic observations. Int J Gynecol Pathol. 2002;21:134–40.

    PubMed  Google Scholar 

  112. Gray HJ, Garcia R, Tamimi HK, et al. Glassy cell carcinoma of the cervix revisited. Gynecol Oncol. 2002;85:274–7.

    PubMed  Google Scholar 

  113. Ferry JA, Scully RE. “Adenoid cystic” carcinoma and adenoid basal carcinoma of the uterine cervix. A study of 28 cases. Am J Surg Pathol. 1988;12:134–44.

    PubMed  CAS  Google Scholar 

  114. Grayson W, Taylor LF, Cooper K. Adenoid cystic and adenoid basal carcinoma of the uterine cervix: comparative morphologic, mucin, and immunohistochemical profile of two rare neoplasms of putative ‘reserve cell’ origin. Am J Surg Pathol. 1999;23:448–58.

    PubMed  CAS  Google Scholar 

  115. Dominguez-Malagon HR, Flores-Flores G, Meneses Garcia A, et al. Adenoid cystic carcinoma of the uterine cervix. A tumor with myoepithelial cells and neuroendocrine differentiation. Int J Surg Pathol. 1996;4:77–82.

    Google Scholar 

  116. Grayson W, Taylor L, Cooper K. Detection of integrated high risk human papillomavirus in adenoid cystic carcinoma of the uterine cervix. J Clin Pathol. 1996;49:805–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  117. Parwani AV, Smith Sehdev AE, Kurman RJ, Ronnett BM. Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: clinicopathologic features, human papillomavirus DNA detection, and p16 expression. Hum Pathol. 2005;36:82–90.

    PubMed  CAS  Google Scholar 

  118. Albores-Saavedra J, Manivel C, Mora A, Vuitch F, Milchgrub S, Gould E. The solid variant of adenoid cystic carcinoma of the cervix. Int J Gynecol Pathol. 1992;11:2–10.

    PubMed  CAS  Google Scholar 

  119. Grayson W, Cooper K. A reappraisal of “basaloid carcinoma” of the cervix, and the differential diagnosis of basaloid cervical neoplasms. Adv Anat Pathol. 2002;9:290–300.

    PubMed  Google Scholar 

  120. Brainard JA, Hart WR. Adenoid basal epitheliomas of the uterine cervix: a reevaluation of distinctive cervical basaloid lesions currently classified as adenoid basal carcinoma and adenoid basal hyperplasia. Am J Surg Pathol. 1998;22:965–75.

    PubMed  CAS  Google Scholar 

  121. Chen T-D, Chuang H-C, Lee L. Adenoid basal carcinoma of the uterine cervix: clinicopathologic features of 12 cases with reference to CD117 expression. Int J Gynecol Pathol. 2012;31:25–32.

    PubMed  Google Scholar 

  122. Lemoine NR, Hall PA. Epithelial tumors metastatic to the uterine cervix. A study of 33 cases and review of the literature. Cancer. 1986;57:2002–5.

    PubMed  CAS  Google Scholar 

  123. McCluggage WG, Hirschowitz L, Wilson GE, et al. Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. Am J Surg Pathol. 2011;35:289–94.

    PubMed  Google Scholar 

  124. Hoogduin KJ, Hopman AN, Ramaekers FC, McCluggage WG, Smedts F. BCL2 and keratin 5 define the uterine-cervix-isthmus junction, a transition between endocervical and tubal-like epithelium. Int J Gynecol Pathol. 2013;32:122–30.

    PubMed  CAS  Google Scholar 

  125. Jordan LB, Al-Nafussi A. Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma. Int J Gynecol Cancer. 2002;12:42–8.

    PubMed  CAS  Google Scholar 

  126. Scott M, Lyness RW, McCluggage WG. Atypical reactive proliferation of endocervix: a common lesion associated with endometrial carcinoma and likely related to prior endometrial sampling. Mod Pathol. 2006;19:470–4.

    PubMed  Google Scholar 

  127. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG. Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol. 2010;18:138–43.

    PubMed  CAS  Google Scholar 

  128. Tambouret R, Clement PB, Young RH. Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIb endometrial carcinoma liable to be misinterpreted as an independent carcinoma or a benign lesion. Am J Surg Pathol. 2003;27:1080–8.

    PubMed  Google Scholar 

  129. McCluggage WG, Hurrell DP, Kennedy K. Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol. 2010;34:735–41.

    PubMed  Google Scholar 

  130. Malpica A, Deavers MT. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary. Int J Gynecol Pathol. 2011;30:613–9.

    PubMed  Google Scholar 

  131. Yemelyanova A, Ji H, Shih IM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504–14.

    PubMed  Google Scholar 

  132. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328–33.

    PubMed  Google Scholar 

  133. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: “all or nothing” staining is of importance. Histopathology. 2011;59:786–8.

    PubMed  Google Scholar 

  134. Kobel M, Reuss A, Du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222:191–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Royal Victoria Hospital, Belfast, UK

    W. Glenn McCluggage

Authors
  1. W. Glenn McCluggage
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

McCluggage, W.G. (2014). Malignant Glandular Lesions of the Cervix. In: Cellular Pathology of Glandular Lesions and Uncommon Neoplasms of the Cervix. Springer, London. https://doi.org/10.1007/978-1-4471-2210-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2210-4_4

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2209-8

  • Online ISBN: 978-1-4471-2210-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation